Latest updates on the coronavirus and heart disease
Over 40 leading organizations who represent patients, product development partnerships, youth groups, researchers and industry, are urging Heads of State and Government to ratify the African Medicines Treaty in order to simplify regulatory frameworks and enable patients across Africa to access effective, quality medicines. The statement, issued today by the International Alliance of Patients Organizations (IAPO) and supported by WHF, highlights the need for a competent continent-wide regulatory authority to approve and monitor vaccines, repurposed medicines, innovative medicines, and health technologies.
“As the global organization looking after the interests of the African cardiovascular community, the World Heart Federation, expresses its full support for the ratification of the African Medicines Treaty, which is urgently required now. We need to ensure a harmonized regulatory framework in which patients across the African continent receive safe and effective medicine, and the treatment they need in time, without delays. This is particularly needed for essential medicines such as penicillin in the prevention of Rheumatic Heart Disease. We join the call of other patient and civil society organizations, as well as the health and pharmaceutical industry, in the confidence that this will save lives”, added Prof Fausto Pinto, WHF President.
The statement also notes that a unified regulatory system would greatly contribute to combating falsified and substandard medicinal products and offer more opportunities to boost the development of scientific activities in the continent. The Treaty has so far been signed by 19 countries, and 8 out of the necessary 15 have already ratified it.
Patients, Civil Society and Youth Organisations, Products Development Partnerships, Health and Pharmaceutical Industries, and all stakeholders who are striving to improve global public health – welcome the African Medicines Agency (AMA) Treaty made at the 32nd ordinary session of the Assembly of the African Union (AU) in 2019. We now call for all AU Member States to ratify the Treaty, which has already been signed by 19 countries and ratified by 8 countries. This is a strong commitment from AU Member States and we therefore urge all countries of the AU to ratify the Treaty as a matter of priority.
This is a strong commitment from AU Member States and we therefore urge all countries of the AU to ratify the Treaty as a matter of priority. We believe it is critical to establish a continental regulatory body to reduce the complexity of regulatory frameworks and hence to enable all patients in Africa to have timely access to quality medicines that are safe and effective. This new agency is an integral part of the WHO Global Patient Safety Plan 2020-2030. We support the WHO African Region commitment towards the African Medicines Agency delivered by the Kenyan government at the WHO Executive Board in January 2021.
The COVID-19 pandemic has highlighted the importance of regulatory harmonisation in the context of public health emergencies and the need for a competent continent-wide regulatory authority to approve and monitor vaccines, repurposed medicines, innovative medicines and health technologies, in a timely manner.
Furthermore, a strong unified regulatory system would greatly contribute to combating falsified and substandard medicinal products on the African continent. Coordinated market surveillance, centralised information collection and sharing of data between countries is expected to complement and strengthen national efforts to reduce the circulation of falsified products and increase access to safe and innovative products.
The establishment of the African Medicines Agency will open-up more opportunities to boost local manufacturing capacities, country participation in clinical research and other scientific development activities.
Considering this, we call for:
Voices of Chagas: a disease that knows no borders
WHF, together with Servier and Global Heart Hub, launches "Use Heart to Act Now on Angina"
The cost of inaction on diabetes and hypertension